

Oxidien Pharmaceuticals Announces Completion of Asset Sale

LEXINGTON, MA, USA, December 28, 2023 /EINPresswire.com/ -- Oxidien Pharmaceuticals ("Oxidien") announced today that it has completed the sale of its enzyme technologies and enzyme therapeutic assets. The buyer, Orenzymes LLC, is a private biopharmaceutical company that owns complementary technologies and intends to continue development of Oxidien's lead candidates for hyperoxaluria. Financial terms of the deal were undisclosed.

Oxidien is a clinical-stage biopharmaceutical company addressing a large unmet need in kidney disease. The company develops novel oral enzymes as potential drug candidates to treat secondary hyperoxaluria, including enteric hyperoxaluria (EH). EH is a condition with high morbidity, including kidney inflammation, recurrent kidney stones, progressive chronic kidney disease and in severe cases end-stage kidney disease resulting in a significant burden on the healthcare system.

Oxidien's lead candidate was evaluated in a prospective, double-blind, randomized, placebo-controlled clinical study in 33 healthy volunteers on a controlled high-oxalate diet. No serious adverse events and no product-related adverse events occurred. The baseline corrected within-subject mean reduction in 24-hour urinary oxalate excretion was 29% ($P < 0.001$), with 94% of participants responding to the treatment (demonstrating $>5\%$ reduction). All pre-determined endpoints were met. This clinical study provides additional support for oral enzyme effectiveness in hyperoxaluria ([Quintero et al., 2020](#)).

Oxidien's asset portfolio include both potential drug candidates and food ingredients. The technologies and assets were spun out from an originator company, Captozyme, Inc., in 2019 as part of a separate transaction, the acquisition of Captozyme, a process development service organization.

About Oxidien Pharmaceuticals

Oxidien is a clinical-stage biopharmaceutical company addressing a large unmet need in kidney disease. The company develops novel oral enzymes as potential drug candidates to treat secondary hyperoxaluria. Oxidien has a strong intellectual property position with issued and pending patents in all major markets. The leadership team has a proven track record of founding, operating, and transacting biotechnology businesses. For additional information on Oxidien please visit www.oxidien.com.

Helena Cowley

Cowley Advisors, LLC
+1 352-672-5320
helena@cowleyadvisorsllc.com

This press release can be viewed online at: <https://www.einpresswire.com/article/677397680>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.